ClinicalTrials.gg
Active, not recruitingNCT06390995Updated Jun 16, 2026Results posted

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

A Phase 1/2 interventional study of TAK-853 in Ovarian Cancer and Solid Tumors, sponsored by Takeda. Active, not recruiting at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Takeda · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. mirvetuximab soravtansine · Ovarian Neoplasms.

Enrollment
11th of 12
28 · median 80
Started
2024
the only one that year
Phase 1/2
Only one
of the 12
Registered
9th of 12
by date
Lead sponsor
1 of 12
Takeda

Among the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, this one is the 11th largest by enrollment, is the only one that started in 2024, is the only one in phase 1/2, and was the 9th registered.

Ovarian Neoplasms

3,389 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About mirvetuximab soravtansine

mirvetuximab soravtansine: first FDA approval 2022 (ELAHERE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mirvetuximab soravtansine in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853 stays in their blood over time.

The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle.

The participant will be in the study for about 9 months in Phase 1 Part and for about 24 months in Phase 2 Part. The study doctors will check for side effects from the study treatments.

03

Conditions studied

  • Ovarian Cancer
  • Solid Tumors

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1 part:

  1. Diagnosis, allowable prior therapy, and disease measurability requirements:

    1. All participants must have a documented, following advanced solid tumor known to express folate receptor alpha (FR alpha), that is resistant or to standard treatment, for which no standard treatment is available, or the participant refuses standard therapy.

      • Ovarian cancer
      • Endometrial cancer
      • Non-small cell lung cancer (NSCLC)
      • Triple-negative breast cancer (TNBC)
      • Cholangiocarcinoma
      • Colorectal cancer (CRC)
      • Gastro-esophageal adenocarcinoma Note: Participants with a solid tumor type other than the above will be eligible as long as there is prior documentation of tumor FR alpha expression.
    2. All participants without prior documentation of tumor FR alpha expression by immunohistochemistry (IHC) must be willing to provide an block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for IHC confirmation of FR alpha positivity of >=1% of viable tumor cells with membrane staining at >=1+ intensity for entry into Phase 1 part
    3. There is no upper limit on the number of prior cytotoxic or targeted therapies the participant may have received. Participants may have received prior treatment with compounds targeting folate receptor excluding MIRV.
    4. Participants must have measurable or non- (such as large abdominal masses that cannot be accurately measured) according to (RECIST) 1.1.
  2. Participant must have an Performance Status (ECOG PS) of 0 or 1
  3. Time from Prior Therapy:

    • Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for prior nitrosoureas or mitomycin C)
    • FR alpha-targeted therapy: five half-lives or four weeks, whichever is longer
    • Radiotherapy: wide-field radiotherapy (e.g. affecting at least 30% of the bone marrow) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study drug
  4. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities
  5. Major surgery must be completed four weeks prior to first dose of TAK-853. Participants must have recovered or stabilized from the side effects prior to study treatment.
  6. Participants must have adequate hematologic, liver and kidney function as defined by the following parameters:

    1. (ANC) >= 1.5*10\^9/L (1,500/microliter) without granulocyte colony stimulating factor (G-CSF) in the prior 10 days or long-acting white blood cell (WBC) growth factors in the prior 20 days
    2. count >= 100.0*10\^9/L (100,000/microliter; without platelet transfusion in the prior 10 days)
    3. >= 9.0 g/dL without packed red blood cell (PRBC) transfusion in the prior 21 days
    4. Serum creatinine =\< 1.5* (ULN) or estimated of >= 30 mL/minute (as calculated using the Cockcroft Gault equation),
    5. (AST) =\< 2.5* ULN; alanine aminotransferase (ALT) =\< 2.5* ULN (AST, ALT \< 5* ULN if liver ), and
    6. Total =\< 1.5* ULN (participants with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0* ULN)
  7. Participants with central nervous system (CNS) disease involvement are eligible if they have had resected or have received radiation therapy ending at least 4 weeks prior to study Day 1 and they meet all of the following criteria:

<!-- -->

  1. Residual neurological symptoms =\< Grade 1
  2. No dexamethasone requirement, and
  3. Follow-up MRI shows no progression of treated lesions and no new lesions appearing.

Phase 2 part:

  1. Participants must have a confirmed diagnosis of high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  2. Participants must have platinum-resistant disease:

    1. Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response (complete response [CR] or partial response [PR]) and then progressed between > 3 months and =\< 6 months after the last dose date of platinum
    2. Participants who have received 2 or 3 lines of platinum therapy must have progressed on or within 6 months after the date of the last dose of platinum Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression Note: Participants who are primary platinum-refractory during front-line treatment are excluded (see exclusion criteria)
  3. Participants must have progressed radiographically on or after their most recent
  4. Participants must be willing to provide an archival tumor tissue block or slides, or undergo procedure to obtain a new biopsy using a low risk, medically routine procedure for IHC confirmation of FR alpha expression (reported as "positive") as defined by the Ventana FOLR1 Assay. Tumors must be confirmed FR alpha-high as defined by FR alpha positivity of >=75% of viable tumor cells with membrane staining at >=2+ intensity for entry into the Phase 2.
  5. Participants must have at least one lesion that meets the definition of measurable disease by RECIST v1.1 criteria (radiologically measured by the Investigator).
  6. Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single-agent therapy is appropriate as the next line of treatment:

    a. +- adjuvant considered one line of therapy b. Maintenance therapy (e.g., bevacizumab, poly-ADP ribose polymerase [PARP] inhibitors) will be considered as part of the preceding line of therapy (i.e., not counted independently) c. Therapy changed due to toxicity in the absence of progression will be considered as part of the same line (i.e., not counted independently) d. Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance

  7. Participant must have an ECOG PS of 0 or 1
  8. Time from prior therapy:

    1. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)
    2. Focal radiation completed at least 2 weeks prior to first dose of study drug
  9. Participants must have stabilized or recovered (Grade 1 or baseline) from all prior therapy-related toxicities
  10. Major surgery must be completed at least 4 weeks prior to first dose and the participant must have recovered or stabilized from the side effects of prior surgery
  11. Participants must have adequate hematologic, liver, and kidney functions defined as:

    1. ANC >= 1.5* 10\^9/L (1,500/microliter) without G-CSF in the prior 10 days or long-acting WBC growth factors in the prior 20 days
    2. Platelet count >= 100* 10\^9/L (100,000/microliter) without platelet transfusion in the prior 10 days
    3. Hemoglobin >= 9.0 g/dL without PRBC transfusion in the prior 21 days
    4. Serum creatinine =\< 1.5* ULN or estimated creatinine clearance of >= 30 mL/minute (as calculated using the Cockcroft Gault equation).
    5. AST and ALT =\< 3.0* ULN
    6. Total bilirubin =\< 1.5* ULN (participants with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \< 3.0* ULN)
    7. Serum albumin >= 2 g/dL

Exclusion criteria

Exclusion Criteria:

Phase 1 part:

  1. Participant with > Grade 1 peripheral neuropathy per National Cancer Institute (NCI CTCAE) v5.0
  2. Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision.
  3. Serious concurrent illness, including, but not limited to the following:

    1. active infection including - Active or C infection (whether or not on active antiviral therapy)

      - (HIV) infection

      - Active cytomegalovirus infection

      - Active COVID-19/SARS-CoV-2 infection. Although SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines and standards

      - Any other known concurrent infectious disease requiring IV antibiotics within 2 weeks before starting study drug Note: Testing at screening for hepatitis is required, while not required for the remaining infections above unless clinically indicated. Participants with known hepatitis B surface antigen seropositivity and/or detectable virus RNA will be excluded. Participants who have positive hepatitis B core antibody and/or hepatitis B surface antibody can be enrolled but must have an undetectable serum hepatitis B virus DNA. Participants who have positive hepatitis C virus antibody must have an undetectable hepatitis C virus RNA serum level. Participants will be monitored and managed according to Guideline for the prevention of therapy or chemotherapy-induced reactivation of hepatitis B virus infection (The Japan Society of Hepatology 2022).

    2. Participants with clinically significant cardiac disease including, but not limited to, any one of the following:

      - Myocardial infarction =\< 6 months prior to first dose of study medication

      - Unstable angina pectoris

      - Uncontrolled congestive heart failure ( > class II)

      - Uncontrolled >= Grade 3 hypertension (per NCI CTCAE v5.0)

      - Uncontrolled cardiac arrhythmias

      - Severe aortic stenosis

      • >= Grade 3 cardiac toxicity following prior chemotherapy
    3. History of multiple sclerosis or other demyelinating disease, Lambert-Eaton syndrome (paraneoplastic syndrome), history of hemorrhagic or ischemic stroke within the last six months, or alcoholic liver disease.
    4. Previous clinical diagnosis of interstitial lung disease (ILD), including pneumonitis.
  4. Any other concomitant anti-cancer treatment such as immunotherapy, biotherapy, radiotherapy, chemotherapy, investigative therapy, or high-dose ; however, low-dose steroids and Luteinizing Hormone Releasing Hormone (LHRH) at doses that have been stable for >= 14 days are permitted for participants with prostate cancer
  5. Known to previous monoclonal antibody therapy or maytansinoids, or study drugs and/or any of their
  6. Prior history of solid tumor within the last 3 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer (participants must have shown no evidence of active disease for 2 years prior to enrollment)
  7. Participants with required use of folate-containing supplements (e.g., folate deficiency)
  8. Participants who have received prior or autologous bone marrow transplants

Phase 2 part:

  1. Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade or borderline ovarian tumor
  2. Participants with primary platinum- disease, defined as disease that did not respond to (CR or PR) or has progressed within 3 months of the last dose of platinum-containing chemotherapy
  3. Participants with prior wide-field radiotherapy affecting at least 20% of the bone marrow
  4. Participants with > Grade 1 peripheral neuropathy per NCI CTCAE v5.0
  5. Participants with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and/or monocular vision
  6. Participants with serious concurrent illness or clinically relevant active infection, including, but not limited to the following:

    1. Active hepatitis B or C infection (whether or not on active antiviral therapy)
    2. HIV infection
    3. Active cytomegalovirus infection
    4. Active COVID-19/SARS-CoV-2 infection. Although SARS-CoV-2 testing is not mandatory for study entry, testing should follow local clinical practice guidelines and standards.
    5. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks before starting study drug Note: Testing at screening for hepatitis (a) is required, while not required for the remaining infections above (b-e) unless clinically indicated.

Participants with known hepatitis B surface antigen seropositivity and/or detectable hepatitis C virus RNA will be excluded. Participants who have positive hepatitis B core antibody and/or hepatitis B surface antibody can be enrolled but must have an undetectable serum hepatitis B virus DNA.

Participants who have positive hepatitis C virus antibody must have an undetectable hepatitis C virus RNA serum level. Participants will be monitored and managed according to Guideline for the prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection (The Japan Society of Hepatology 2022).

7. Participants with history of multiple sclerosis or other demyelinating disease and/or Lambert-Eaton syndrome (paraneoplastic syndrome) 8. Participants with clinically significant cardiac disease including, but not limited to, any one of the following:

  1. Myocardial infarction =\< 6 months prior to first dose of study medication
  2. Unstable angina pectoris
  3. Uncontrolled congestive heart failure (New York Heart Association > class II)
  4. Uncontrolled >= Grade 3 hypertension (per NCI CTCAE v5.0)
  5. Uncontrolled cardiac arrhythmias 9. Participants with a history of hemorrhagic or ischemic stroke within six months prior to first dose of TAK-853 10. Participants with a history of cirrhotic liver disease ( Class B or C) 11. Participants with a previous clinical diagnosis of ILD, including pneumonitis 12. Participants with required use of folate-containing supplements (e.g., folate deficiency) 13. Participants with prior hypersensitivity to monoclonal antibodies or maytansinoids 14. Participants with prior treatment with TAK-853 or other FR alpha-targeting agents 15. Participants with untreated or symptomatic 16. Participants with a history of other malignancy within 3 years prior to first dose of TAK-853 Note: does not include tumors with a negligible risk for or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) 17. Prior known hypersensitivity reactions to study drugs and/or any of their excipients
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Phase 1 Part and Phase 2 Part: TAK-853

    TAK-853, 6.0 mg/kg, injection, intravenously (IV), once every 3 weeks. Patients will continue to receive study drug until disease progression, unacceptable toxicity, withdrawal of consent, death, or until the sponsor terminates the study (whichever comes first).

    Drug: TAK-853

Interventions

  • TAK-853 intravenous injection

    Also known as: Mirvetuximab Soravtansine

06

What researchers measure

Primary outcomes

  1. Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1

    DLT was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and defined as any of following events: 1. If re-treatment was not initiated within 14 days due to adverse event (AE) related to protocol treatment; 2. Grade 4 neutropenia for more than 7 days; 3. Grade 3 or 4 neutropenia with single temperature reading \>= 38.3-degree Celsius (°C) or sustained temperature reading of greater than (\>) 38°C for \>1 hour; 4. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except following cases, AEs related to underlying disease, Alopecia, Grade 3 fatigue, Lymphopenia unless accompanied by clinically significant infection, isolated and asymptomatic Grade 3 abnormalities in biochemistry laboratory values that last for less than and equal to (\<=) 7 days including electrolyte abnormalities.

    Time frame: Up to Cycle 1 (up to 21 days)

  2. Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event, or a previous condition that has increased in severity or frequency since the administration of study drug.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  3. Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity

    The severity grade was evaluated as per the NCI CTCAE Version 5.0, where Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living \[ADL\]); Grade 3 was severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Grade 4 was life-threatening consequences; urgent intervention indicated, and Grade 5 was death related to AE. TEAEs were AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurs first.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  4. Phase 1: Number of Participants With Serious TEAEs

    A serious TEAE is any untoward medical occurrence or effect that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, and was an important medical event.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  5. Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation

    TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to study drug discontinuation were reported.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  6. Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption

    TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to infusion interruption were reported.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  7. Phase 1: Number of Participants With TEAEs Leading to Dose Delayed

    TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose delayed were reported.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  8. Phase 1: Number of Participants With TEAEs Leading to Dose Reduction

    TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose reduction were reported.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  9. Phase 1: Number of Participants With Adverse Event of Clinical Interest (AECIs)

    AECIs (serious or nonserious) were those TEAEs which were of scientific and medical concern specific to the TAK-853. AECIs for TAK-853 included: 1. Ocular TEAEs, 2. Pneumonitis TEAEs, 3. Peripheral neuropathy TEAEs and 4. Infusion related TEAEs.

    Time frame: From start of study drug up to 30 days after last dose (up to 3.7 months)

  10. Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    ORR was defined as the percentage of participants who achieved a confirmed Partial Response (PR) or confirmed Complete Response (CR) during the study using RECIST 1.1. Complete response (CR): Disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 millimeters (mm). Partial response (PR): At least a 30% decrease in the sum of diameters (SoD of target lesions, taking as reference the baseline SoD).

    Time frame: Up to 7.2 months

Secondary outcomes

  1. Phase 1: Maximum Observed Plasma Concentration (Cmax) of TAK-853 and Total Antibody (TAb)

    Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. Cmax of TAK-853 and TAb were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  2. Phase 1: Cmax of N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)- Maytansine (DM4) and S-methyl DM4

    PK parameters were calculated using standard non-compartmental methods. Cmax of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  3. Phase 1: Area Under the Plasma Concentration-Time Curve Until Tlast (AUClast) and Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of TAK-853 and TAb

    PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of TAK-853 and TAb were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  4. Phase 1: AUClast and AUCinf of DM4 and S-methyl DM4

    PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  5. Phase 1: Terminal Half-Life (t1/2) of TAK-853, TAb, DM4 and S-methyl DM4

    PK parameters were calculated using standard non-compartmental methods. t1/2 of TAK-853, TAb, DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  6. Phase 1: Total Clearance (CL) of TAK-853 and TAb

    PK parameters were calculated using standard non-compartmental methods. CL of TAK-853 and TAb were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  7. Phase 1: Apparent Clearance (CL/F) of DM4 and S-methyl DM4

    PK parameters were calculated using standard non-compartmental methods. CL/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  8. Phase 1: Volume of Distribution at Steady State (Vss) of TAK-853, TAb and Apparent Volume of Distribution During the Terminal Phase (VZ/F) of DM4 and S-methyl DM4

    PK parameters were calculated using standard non-compartmental methods. Vss of TAK-853, TAb and VZ/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion

  9. Number of Participants With Immunogenicity of TAK-853

    Blood samples were collected to measure the presence of TAK-853 antibodies (ADA). Seronegative was defined as a participant with negative ADA at baseline and negative ADA at post-treatment. Treatment-emergent ADA was defined as a participant with negative ADA at baseline and positive ADA at post-treatment. Treatment-unaffected ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was less than or equal to 4-fold compared to baseline. Treatment-enhanced ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was greater than 4-fold compared to baseline.

    Time frame: From start of study drug up to 8.2 months

  10. Phase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1

    DOR was defined as the time from the first observation of CR/PR (whichever is first recorded) to the first date at which progressive disease is objectively documented per RECIST 1.1, or death due to any cause, whichever occurs first. DOR was estimated using the Kaplan-Meier method.

    Time frame: From first documented confirmed CR or PR until first documentation of PD (up to 7.2 months)

  11. Phase 2: Plasma Concentrations of TAK-853 and TAb

    Plasma concentrations of TAK-853 and TAb were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion

  12. Phase 2: Plasma Concentrations of DM4 and S-methyl DM4

    Plasma concentrations of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

    Time frame: Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion

07

Results

Posted Jun 16, 2026

Participant flow

Participants took part in the study at 15 investigative sites in Japan from 20 May 2024.

Participant flow — Overall Study
MilestonePhase 1: TAK-853, 6 mg/kgPhase 2: TAK-853, 6 mg/kg
Started325
Completed30
Not completed025
Withdrew: Death01
Withdrew: Still on study024

Outcome measures

PrimaryPhase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1

DLT was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and defined as any of following events: 1. If re-treatment was not initiated within 14 days due to adverse event (AE) related to protocol treatment; 2. Grade 4 neutropenia for more than 7 days; 3. Grade 3 or 4 neutropenia with single temperature reading \>= 38.3-degree Celsius (°C) or sustained temperature reading of greater than (\>) 38°C for \>1 hour; 4. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except following cases, AEs related to underlying disease, Alopecia, Grade 3 fatigue, Lymphopenia unless accompanied by clinically significant infection, isolated and asymptomatic Grade 3 abnormalities in biochemistry laboratory values that last for less than and equal to (\<=) 7 days including electrolyte abnormalities.

Time frame:
Up to Cycle 1 (up to 21 days)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 10
PrimaryPhase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. This includes any newly occurring event, or a previous condition that has increased in severity or frequency since the administration of study drug.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)3
PrimaryPhase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity

The severity grade was evaluated as per the NCI CTCAE Version 5.0, where Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living \[ADL\]); Grade 3 was severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Grade 4 was life-threatening consequences; urgent intervention indicated, and Grade 5 was death related to AE. TEAEs were AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurs first.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity2
PrimaryPhase 1: Number of Participants With Serious TEAEs

A serious TEAE is any untoward medical occurrence or effect that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, and was an important medical event.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Serious TEAEs
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With Serious TEAEs2
PrimaryPhase 1: Number of Participants With TEAEs Leading to Drug Discontinuation

TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to study drug discontinuation were reported.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation1
PrimaryPhase 1: Number of Participants With TEAEs Leading to Infusion Interruption

TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to infusion interruption were reported.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption0
PrimaryPhase 1: Number of Participants With TEAEs Leading to Dose Delayed

TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose delayed were reported.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With TEAEs Leading to Dose Delayed
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With TEAEs Leading to Dose Delayed0
PrimaryPhase 1: Number of Participants With TEAEs Leading to Dose Reduction

TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first. Number of participants with TEAEs leading to dose reduction were reported.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With TEAEs Leading to Dose Reduction
ParticipantsPhase 1: TAK-853, 6 mg/kg
Phase 1: Number of Participants With TEAEs Leading to Dose Reduction0
PrimaryPhase 1: Number of Participants With Adverse Event of Clinical Interest (AECIs)

AECIs (serious or nonserious) were those TEAEs which were of scientific and medical concern specific to the TAK-853. AECIs for TAK-853 included: 1. Ocular TEAEs, 2. Pneumonitis TEAEs, 3. Peripheral neuropathy TEAEs and 4. Infusion related TEAEs.

Time frame:
From start of study drug up to 30 days after last dose (up to 3.7 months)
Reported as:
Count of participants · Participants
Phase 1: Number of Participants With Adverse Event of Clinical Interest (AECIs)
ParticipantsPhase 1: TAK-853, 6 mg/kg
Ocular TEAEs1
Pneumonitis TEAEs0
Peripheral neuropathy TEAEs2
Infusion-related TEAEs0
PrimaryPhase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

ORR was defined as the percentage of participants who achieved a confirmed Partial Response (PR) or confirmed Complete Response (CR) during the study using RECIST 1.1. Complete response (CR): Disappearance of all target lesions. All pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 millimeters (mm). Partial response (PR): At least a 30% decrease in the sum of diameters (SoD of target lesions, taking as reference the baseline SoD).

Time frame:
Up to 7.2 months
Reported as:
Number · percentage of participants
Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
percentage of participantsPhase 2: TAK-853, 6 mg/kg
Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)44 (27.0 to 62.1)
SecondaryPhase 1: Maximum Observed Plasma Concentration (Cmax) of TAK-853 and Total Antibody (TAb)

Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods. Cmax of TAK-853 and TAb were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Phase 1: Maximum Observed Plasma Concentration (Cmax) of TAK-853 and Total Antibody (TAb)
micrograms per milliliter (mcg/mL)Phase 1: TAK-853, 6 mg/kg
At Cycle 1: TAK-853128.3 ± 15.275
At Cycle 1: TAb134.3 ± 21.962
At Cycle 3: TAK-853125.5 ± 4.9497
At Cycle 3: TAb160.0 ± 16.971
SecondaryPhase 1: Cmax of N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)- Maytansine (DM4) and S-methyl DM4

PK parameters were calculated using standard non-compartmental methods. Cmax of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · nanograms per milliliter (ng/mL)
Phase 1: Cmax of N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)- Maytansine (DM4) and S-methyl DM4
nanograms per milliliter (ng/mL)Phase 1: TAK-853, 6 mg/kg
At Cycle 1: DM45.360 ± 1.7317
At Cycle 1: S-methyl DM410.04 ± 4.7816
At Cycle 3: DM44.875 ± 1.3081
At Cycle 3: S-methyl DM49.885 ± 4.1224
SecondaryPhase 1: Area Under the Plasma Concentration-Time Curve Until Tlast (AUClast) and Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of TAK-853 and TAb

PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of TAK-853 and TAb were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · milligrams*hours/milliliter (mg*h/mL)
Phase 1: Area Under the Plasma Concentration-Time Curve Until Tlast (AUClast) and Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of TAK-853 and TAb
milligrams*hours/milliliter (mg*h/mL)Phase 1: TAK-853, 6 mg/kg
AUClast: At Cycle 1: TAK-85314.19 ± 1.4178
AUClast: At Cycle 1: TAb18.12 ± 1.7871
AUClast: At Cycle 3: TAK-85312.64 ± 1.8875
AUClast: At Cycle 3: TAb22.03 ± 5.1276
AUCinf: At Cycle 1: TAK-85314.93 ± 1.5524
AUCinf: At Cycle 1: TAb22.31 ± 1.7973
AUCinf: At Cycle 3: TAK-85315.52 ± 0.20264
AUCinf: At Cycle 3: TAb35.77 ± 1.8223
SecondaryPhase 1: AUClast and AUCinf of DM4 and S-methyl DM4

PK parameters were calculated using standard non-compartmental methods. AUClast and AUCinf of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · nanograms*hours/milliliter (ng*h/mL)
Phase 1: AUClast and AUCinf of DM4 and S-methyl DM4
nanograms*hours/milliliter (ng*h/mL)Phase 1: TAK-853, 6 mg/kg
AUClast: Cycle 1: DM4243.8 ± 95.378
AUClast: Cycle 1: S-methyl DM41935 ± 1279.3
AUClast: Cycle 3: DM4214.7 ± 58.406
AUClast: Cycle 3: S-methyl DM41444 ± 368.31
AUCinf: Cycle 1: DM4258.9 ± 94.442
AUCinf: Cycle 1: S-methyl DM42273 ± 1562.1
AUCinf: Cycle 3: DM4245.8 ± 69.877
AUCinf: Cycle 3: S-methyl DM41909 ± 939.42
SecondaryPhase 1: Terminal Half-Life (t1/2) of TAK-853, TAb, DM4 and S-methyl DM4

PK parameters were calculated using standard non-compartmental methods. t1/2 of TAK-853, TAb, DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · hours
Phase 1: Terminal Half-Life (t1/2) of TAK-853, TAb, DM4 and S-methyl DM4
hoursPhase 1: TAK-853, 6 mg/kg
At Cycle 1: TAK-853115.1 ± 6.3839
At Cycle 1: TAb210.2 ± 44.702
At Cycle 1: DM472.37 ± 12.508
At Cycle 1: S-methyl DM4158.9 ± 32.608
At Cycle 3: TAK-853130.3 ± 12.170
At Cycle 3: TAb234.1 ± 51.979
At Cycle 3: DM473.85 ± 18.392
At Cycle 3: S-methyl DM4121.5 ± 17.425
SecondaryPhase 1: Total Clearance (CL) of TAK-853 and TAb

PK parameters were calculated using standard non-compartmental methods. CL of TAK-853 and TAb were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · milliliters per hour (mL/h)
Phase 1: Total Clearance (CL) of TAK-853 and TAb
milliliters per hour (mL/h)Phase 1: TAK-853, 6 mg/kg
At Cycle 1: TAK-85321.04 ± 0.53430
At Cycle 1: TAb14.09 ± 1.3011
At Cycle 3: TAK-85319.83 ± 2.5663
At Cycle 3: TAb8.653 ± 1.6664
SecondaryPhase 1: Apparent Clearance (CL/F) of DM4 and S-methyl DM4

PK parameters were calculated using standard non-compartmental methods. CL/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · liters per hour (L/h)
Phase 1: Apparent Clearance (CL/F) of DM4 and S-methyl DM4
liters per hour (L/h)Phase 1: TAK-853, 6 mg/kg
At Cycle 1: DM425.26 ± 8.6819
At Cycle 1: S-methyl DM44.167 ± 3.4983
At Cycle 3: DM424.41 ± 3.5361
At Cycle 3: S-methyl DM43.381 ± 1.2256
SecondaryPhase 1: Volume of Distribution at Steady State (Vss) of TAK-853, TAb and Apparent Volume of Distribution During the Terminal Phase (VZ/F) of DM4 and S-methyl DM4

PK parameters were calculated using standard non-compartmental methods. Vss of TAK-853, TAb and VZ/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
Reported as:
Mean · liters (L)
Phase 1: Volume of Distribution at Steady State (Vss) of TAK-853, TAb and Apparent Volume of Distribution During the Terminal Phase (VZ/F) of DM4 and S-methyl DM4
liters (L)Phase 1: TAK-853, 6 mg/kg
At Cycle 1: TAK-8533.135 ± 0.19878
At Cycle 1: TAb3.854 ± 0.49267
At Cycle 1: DM42532 ± 360.89
At Cycle 1: S-methyl DM4881.8 ± 644.96
At Cycle 3: TAK-8533.312 ± 0.19530
At Cycle 3: TAb2.771 ± 0.072400
At Cycle 3: DM42554 ± 271.07
At Cycle 3: S-methyl DM4577.3 ± 129.83
SecondaryNumber of Participants With Immunogenicity of TAK-853

Blood samples were collected to measure the presence of TAK-853 antibodies (ADA). Seronegative was defined as a participant with negative ADA at baseline and negative ADA at post-treatment. Treatment-emergent ADA was defined as a participant with negative ADA at baseline and positive ADA at post-treatment. Treatment-unaffected ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was less than or equal to 4-fold compared to baseline. Treatment-enhanced ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was greater than 4-fold compared to baseline.

Time frame:
From start of study drug up to 8.2 months
Reported as:
Count of participants · Participants
Number of Participants With Immunogenicity of TAK-853
ParticipantsPhase 1: TAK-853, 6 mg/kgPhase 2: TAK-853, 6 mg/kg
Seronegative221
Treatment-emergent ADA02
Treatment-unaffected ADA12
Treatment-enhanced ADA00
SecondaryPhase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1

DOR was defined as the time from the first observation of CR/PR (whichever is first recorded) to the first date at which progressive disease is objectively documented per RECIST 1.1, or death due to any cause, whichever occurs first. DOR was estimated using the Kaplan-Meier method.

Time frame:
From first documented confirmed CR or PR until first documentation of PD (up to 7.2 months)
Reported as:
Median · months
Phase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1
monthsPhase 2: TAK-853, 6 mg/kg
Phase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1NA (NA to NA)
SecondaryPhase 2: Plasma Concentrations of TAK-853 and TAb

Plasma concentrations of TAK-853 and TAb were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Phase 2: Plasma Concentrations of TAK-853 and TAb
micrograms per milliliter (mcg/mL)Phase 2: TAK-853, 6 mg/kg
At Cycle 1: TAK-853146.2 ± 29.513
At Cycle 1: TAb138.6 ± 22.013
At Cycle 3: TAK-853145.2 ± 15.550
At Cycle 3: TAb139.2 ± 25.606
SecondaryPhase 2: Plasma Concentrations of DM4 and S-methyl DM4

Plasma concentrations of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.

Time frame:
Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
Reported as:
Mean · nanograms per milliliter (ng/mL)
Phase 2: Plasma Concentrations of DM4 and S-methyl DM4
nanograms per milliliter (ng/mL)Phase 2: TAK-853, 6 mg/kg
At Cycle 1: DM43.352 ± 1.1023
At Cycle 1: S-methyl DM40.3896 ± 0.78352
At Cycle 3: DM43.076 ± 0.65073
At Cycle 3: S-methyl DM43.428 ± 2.5061

Adverse events

Collected over From start of study drug up to 8.2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: TAK-853, 6mg/kg0/3 (0%)2/3 (66.7%)3/3 (100%)
Phase 2: TAK-853, 6 mg/kg2/25 (8%)6/25 (24%)25/25 (100%)
Most frequent serious events
Most frequent serious events
EventPhase 1: TAK-853, 6mg/kgPhase 2: TAK-853, 6 mg/kg
Bile duct stenosisHepatobiliary disorders1/30/25
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/25
Abdominal abscessInfections and infestations0/31/25
Cholecystitis acuteHepatobiliary disorders0/31/25
DiarrhoeaGastrointestinal disorders0/31/25
HeadacheNervous system disorders0/31/25
Oesophageal varices haemorrhageGastrointestinal disorders0/31/25
Pleural effusionRespiratory, thoracic and mediastinal disorders0/31/25
Radius fractureInjury, poisoning and procedural complications0/31/25
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPhase 1: TAK-853, 6mg/kgPhase 2: TAK-853, 6 mg/kg
Neuropathy peripheralNervous system disorders2/30/25
Alanine aminotransferase increasedInvestigations1/39/25
NauseaGastrointestinal disorders0/39/25
Aspartate aminotransferase increasedInvestigations1/38/25
Back painMusculoskeletal and connective tissue disorders1/30/25
DiarrhoeaGastrointestinal disorders1/32/25
KeratopathyEye disorders1/33/25
Platelet count decreasedInvestigations1/36/25
VomitingGastrointestinal disorders1/32/25
Peripheral sensory neuropathyNervous system disorders0/37/25

Baseline characteristics

The safety analysis set included the group of participants who received at least one dose of TAK-853.

Age, Continuous
Age, Continuous(years)Phase 1: TAK-853, 6mg/kgPhase 2: TAK-853, 6 mg/kgTotal
Mean54.33 ± 16.28965.56 ± 10.70964.36 ± 11.58
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: TAK-853, 6mg/kgPhase 2: TAK-853, 6 mg/kgTotal
Female32528
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: TAK-853, 6mg/kgPhase 2: TAK-853, 6 mg/kgTotal
Hispanic or Latino000
Not Hispanic or Latino32528
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: TAK-853, 6mg/kgPhase 2: TAK-853, 6 mg/kgTotal
American Indian or Alaska Native000
Asian32528
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

20 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Apr 2025, 10 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 10 months is below that.

Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
Apr 30, 2024
StartActual
May 20, 2024
Primary completionActual
Apr 16, 2025
CompletionEst.
Mar 19, 2027
Results first posted
Jun 16, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06390995
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 30, 2024
Start date
May 20, 2024
Primary completion
Apr 16, 2025
Completion
Mar 19, 2027 (estimated)
Results posted
Jun 16, 2026
Last update
Jun 16, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirvetuximab soravtansine

Start the discussion